Immunotherapy partners after progression: Right place, right time?

This editorial aims to place the trial of pembrolizumab plus next line chemotherapy by Salous et al. in the context of other clinical trials evaluating different strategies to extend the benefit of immunotherapy after disease progression. Included in this article are the INSIGNA trial, off‐protocol...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 129; no. 2; pp. 181 - 183
Main Authors Rouhani, Sherin J., Bestvina, Christine M.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 15.01.2023
Subjects
Ablation
Chemotherapy
Clinical trials
Humans
Immunotherapy
Monoclonal antibodies
Pembrolizumab
Radiation
Online AccessGet full text
ISSN0008-543X
1097-0142
1097-0142
DOI10.1002/cncr.34558

Cover

More Information
Summary:This editorial aims to place the trial of pembrolizumab plus next line chemotherapy by Salous et al. in the context of other clinical trials evaluating different strategies to extend the benefit of immunotherapy after disease progression. Included in this article are the INSIGNA trial, off‐protocol treatment beyond progression, local ablative therapy with radiation, the recently published Lung‐MAP S1800A study, and a summary of other immunotherapy‐based combinations currently under investigation.
Bibliography:See referenced original article on pages
this issue.
264–71
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
content type line 23
ISSN:0008-543X
1097-0142
1097-0142
DOI:10.1002/cncr.34558